Chodjania Yasmina, Tharaux Pierre-Louis, Ragueneau Isabelle, Dussaule Jean-Claude, Picker Jean-Luc, Funck-Brentano Christian, Jaillon Patrice
Department of Pharmacology, Saint-Antoine Hospital, Assistance Publique-Hopitaux de Paris, France.
Clin Pharmacol Ther. 2002 Jun;71(6):468-78. doi: 10.1067/mcp.2002.124521.
To examine the mechanism of action of dual inhibitors of angiotensin-converting enzyme (ACE) and neutral endopeptidase, also called vasopeptidase inhibitors, we compared the effects of S21402 [(2S)-2-[(2S,3R)-2-thiomethyl-3-phenylbutanamido]propionic acid], which belongs to this pharmacologic class, with those of captopril, an ACE inhibitor, on blood pressure, endocrine parameters, and renal in healthy subjects with hypovolemia.
Ten subjects participated to this double-blind, 2-period, randomized, crossover study. Hypovolemia was induced in these subjects with a 7-day treatment of hydrochlorothiazide. They received a single oral dose of 50 mg captopril or 250 mg S21402 on the last day of diuretic treatment. Blood pressure was measured, and urine and blood samples were collected before and during a 12-hour period after drug administration.
The plasma angiotensin II/angiotensin I ratio and aldosterone concentration decreased to the same degree with both drugs, 3 hours after dosing. Compared with captopril, S21402 increased levels of plasma atrial natriuretic peptide (P <.05) and urinary cyclic guanosine monophosphate (P <.001); these increases were the result of inhibition of neutral endopeptidase activity (P <.001). The increase in plasma renin concentration related to ACE inhibition was less marked (P <.001) after S21402 than after captopril. S21402, but not captopril, increased urinary sodium excretion (P <.05), without modifying blood pressure and creatinine clearance, whereas blood pressure transiently fell after captopril administration (P <.05).
In healthy hypovolemic subjects, the vasopeptidase inhibitor S21402 exhibits a natriuretic effect and does not affect blood pressure or glomerular filtration rate. In these conditions, the acute endocrine, vascular, and renal effects of vasopeptidase inhibition differ from those of ACE inhibition.
为研究血管紧张素转换酶(ACE)和中性内肽酶双重抑制剂(又称血管肽酶抑制剂)的作用机制,我们比较了属于该药理类别的S21402[(2S)-2-[(2S,3R)-2-硫代甲基-3-苯基丁酰胺基]丙酸]与ACE抑制剂卡托普利对低血容量健康受试者血压、内分泌参数和肾脏的影响。
10名受试者参与了这项双盲、两阶段、随机、交叉研究。通过7天的氢氯噻嗪治疗使这些受试者出现低血容量。在利尿治疗的最后一天,他们接受了50mg卡托普利或250mg S21402的单次口服剂量。给药前及给药后12小时内测量血压,并采集尿液和血液样本。
给药3小时后,两种药物使血浆血管紧张素II/血管紧张素I比值和醛固酮浓度下降程度相同。与卡托普利相比,S21402使血浆心钠素水平升高(P<.05),尿环磷酸鸟苷水平升高(P<.001);这些升高是抑制中性内肽酶活性的结果(P<.001)。与卡托普利相比,S21402抑制ACE后血浆肾素浓度的升高不太明显(P<.001)。S21402增加尿钠排泄(P<.05),但不改变血压和肌酐清除率,而卡托普利给药后血压短暂下降(P<.05)。
在健康的低血容量受试者中,血管肽酶抑制剂S21402具有利钠作用,不影响血压或肾小球滤过率。在这些情况下,血管肽酶抑制的急性内分泌、血管和肾脏作用与ACE抑制不同。